A Study of Renal Microvessel Imaging for Chronic Kidney Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Definity, Super-resolution ultrasound imaging.
- Who it may be relevant to
- Registry conditions: Healthy, Chronic Kidney Diseases. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Renal Microvessel Imaging for Characterization of Chronic Kidney Disease
Overview
The purpose of this research is to study the efficacy of ultrasound microvessel imaging for evaluation of Chronic Kidney Disease. Definity is an ultrasound contrast agent currently approved by the FDA for use on the heart, liver, and urinary tract. This study will look at its effectiveness on the kidney.
Interventions
- Drug Definity
Ultrasound contrast agent administered intravenously - Diagnostic test Super-resolution ultrasound imaging
Imaging technology for microvessel imaging. This technology localizes and tracks individual microbubbles (FDA approved ultrasound contrast agents) to map microvessel morphology and flow speed at a spatial resolution about 10 times higher than conventional ultrasound imaging.
Primary outcome measures
- Renal cortex microvessel density [Time frame: Baseline]
- Renal cortex microvessel diameter [Time frame: Baseline]
- Renal blood flow velocity [Time frame: Baseline]
Eligibility criteria
Inclusion criteria
\- Healthy volunteers or Chronic Kidney Disease (CKD) patients with clinically indicated renal biopsy.
Exclusion criteria
- Subjects lacking capacity to consent.
- Vulnerable subjects such as prisoners; pregnant women; nursing mother.
- Subjects with history of hypersensitivity allergic reactions to ultrasound contrast agents.
- Patients with high-risk cardiac diseases.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Non-randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Diagnostic
Study locations
United States · 2 centers
- Mayo Clinic Florida — Jacksonville
- Mayo Clinic Minnesota — Rochester
Identifiers
NCT: NCT05764642 · 22-006499 · R01DK129205